Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India
Authors:
- Pawan KumarPKPawan Kumar
- Arindam RayARArindam Ray
- Amrita KumariAKAmrita Kumari
- Abida SultanaASAbida Sultana
- Rhythm HoraRHRhythm Hora
- Kapil SinghKSKapil Singh
- Rashmi MehraRMRashmi Mehra
- Amanjot KaurAKAmanjot Kaur
- Seema Singh KoshalSKSeema Singh Koshal
- Syed F. QuadriSQSyed F. Quadri
- Shyam Kumar SinghSSShyam Kumar Singh
- Arup Deb RoyARArup Deb Roy
Open Access
Abstract
Background: Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out. Results: The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusions: The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.Keywords
All Related Versions
Funding Information
- Bill & Melinda Gates Foundation (INV-030655)
This publication has 42 references indexed in Scilit:
- Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III studyVaccine, 2024
- Critical factors in the successful expansion of Pneumococcal Conjugate Vaccine in India during the COVID-19 pandemicVaccine: X, 2023
- Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label studyVaccine, 2021
- Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in IndiaInfectious Diseases and Therapy, 2021
- Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in IndiaVaccine, 2021
- Pneumococcal conjugate vaccine introduction in India’s Universal immunization programIndian Pediatrics, 2017
- Access to effective antimicrobials: a worldwide challengeThe Lancet, 2016
- Effectiveness of 2+1 PCV7 vaccination schedules in children under 2 years: A meta-analysis of impact studiesVaccine, 2013
- Serotype replacement in disease after pneumococcal vaccinationThe Lancet, 2011
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009